ArticleScientific reports2020
Neutrophil to lymphocyte ratio and breast cancer risk: analysis by subtype and potential interactions.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Early menarche and breast cancer risk: a systematic review and meta-analysis of 74 case-control studies.Cancer causes & control : CCC · 2026Pooled it
- Intratumoral pro-oxidants promote cancer immunotherapy by recruiting and reprogramming neutrophils to eliminate tumors.Cancer immunology, immunotherapy : CII · 2023Pooled it
- Breast Cancer-Derived AZU1 Educates Neutrophils to Promote Tumor Progression and Metastasis Through PAD4-Dependent Extracellular Trap Formation.Molecular carcinogenesis · 2026Article
- Association of Pretreatment Serum Albumin and Systemic Inflammatory Markers with Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer.Journal of clinical medicine · 2026Article
- Association of Neutrophil-to-Lymphocyte Ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) With Molecular Subtypes of Breast Cancer.Iranian journal of pathology · 2026Article
- Explainable machine learning for breast mass characterization and malignancy risk stratification: multimodal integration of AI-derived structured digital breast tomosynthesis features and peripheral blood immune-inflammatory biomarkers.Frontiers in cell and developmental biology · 2026Article
- Diagnostic value of peripheral blood inflammatory indices for breast cancer grade and immunohistochemical markers: a retrospective observational study.BMC cancer · 2025Observational
- Systemic Immune Profiling Reveals Candidate Biomarkers in Luminal A Breast Cancer: A Comparative Pilot Study.Biomedicines · 2025Article
- Baseline neutrophil-lymphocyte ratio (NLR) predicts toxicity and survival in HR+/HER-2 breast cancer patients treated with CDK4/6 inhibitors.Breast (Edinburgh, Scotland) · 2025Article
- Correlation of Peripheral Neutrophil-to-Lymphocyte Ratio (NLR) with Ki-67 and Other Clinicopathological Parameters of Breast Carcinoma.Indian journal of surgical oncology · 2025Article
- TRAIL induces cytokine production via the NFkB2 pathway promoting neutrophil chemotaxis and neutrophil-mediated immune-suppression in triple negative breast cancer cells.Cancer letters · 2025Article
- Circulating chemokines and leukocytes and their impact on breast cancer prognosis.Discover oncology · 2025Article
- Triple-negative breast cancer modifies the systemic immune landscape and alters neutrophil functionality.NPJ breast cancer · 2025Article
- Integrating traditional biomarkers and emerging predictors to assess neoadjuvant chemotherapy efficacy in breast cancer: a multifactorial analysis of Ki-67, CDK4, EGFR, TILs and ctDNA.BMC women's health · 2024Article
- The effective duration of systemic therapy and the neutrophil-to-lymphocyte ratio predict the surgical advantage of primary tumor resection in patients with de novo stage IV breast cancer: a retrospective study.World journal of surgical oncology · 2024Article
- Article
- Unlocking the complete blood count as a risk stratification tool for breast cancer using machine learning: a large scale retrospective study.Scientific reports · 2024Article
- Extracellular vesicles as a promising source of lipid biomarkers for breast cancer detection in blood plasma.Journal of extracellular vesicles · 2024Article
- Genetic Mutations Associated with Inflammatory Response Caused by HPV Integration in Oropharyngeal Squamous Cell Carcinoma.Biomedicines · 2023Article
- Neutrophil to lymphocyte ratio (NTLR) predicts local control and overall survival after stereotactic body radiotherapy (SBRT) in metastatic sarcoma.Scientific reports · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple studies have found the neutrophil to lymphocyte ratio (NLR) to be associated with adverse breast cancer (BC) prognosis and survival. Very limited data exist on the role of NLR and risk of BC. The BREOGAN study is a population-based case-control study conducted in Galicia, Spain. We examined the WBC- and NLR-BC relationships. The risk of BC increased with increasing levels of neutrophils percentage (NE%) (multivariable OR for the highest category (95% CI) = 2.14 (1.39-3.32), P-trend < 0.001) and of the NLR (multivariable OR for the highest category (95% CI) = 1.93 (1.26-2.97), P-trend < 0.001). Lymphocytes absolute (L#) and percentage (L%) were associated with a decreased risk of BC (multivariable OR for the highest category (95% CI) = 0.54 (0.35-0.83), and 0.51 (0.33-0.79), P-trend = 0.001 and < 0.001, respectively). The NLR-BC association was more pronounced among Luminal A BC (multivariable OR for the highest category (95% CI) = 2.00 (1.17-3.45), P-trend < 0.001), HER2-negative BC (multivariable OR for the highest category (95% CI) = 1.87 (1.16-3.02), P-trend < 0.001), and those with high total cholesterol and low H
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.